Alnylam's Updated $110 FVE Reflects Restructured Sanofi Alliance; Shares Remain Overvalued
We are updating our fair value estimate for RNA therapeutics company Alnylam to $110 per share from $111 to reflect updated terms for the company’s rare-disease alliance with Sanofi and lowered tax forecasts to align with recent U.S. policy changes. While Alnylam will have less exposure to future sales of hemophilia drug fitusiran, the company will now retain global rights to its next-generation patisiran candidate, ALN-TTRsc02, in hereditary ATTR amyloidosis. This alignment makes strategic sens...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.